CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

President Trump signed an executive order Monday that will attempt to bring down the cost of some drugs in the United States — but why are drug prices so high to begin with? On average, Americans pay almost three times as much for prescription drugs as people in other high-income countries like the U.

CMS proposed several changes for the third round of Medicare drug price negotiations, including the potential inclusion of some drugs under Medicare Part B, in a draft guidance published May 12. The guidance aims to increase program transparency,

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

CMS said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year. For the first time, the list would include drugs payable under Medicare Part B - which covers medicines administered in a doctor's office or hospital - in addition to prescription drugs covered under Medicare Part D,

The editorial board of the Wall Street Journal is criticizing President Trump over an executive order expanding drug price controls. “For that trade we could have elected Democrats,”